-
Mashup Score: 0Licensing agreement reached for contrast agent for use in patients with prostate cancer - 2 hour(s) ago
A late phase 3 trial evaluating the agent is underway at several clinics in Europe.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0
“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2Dr. Shakuri-Rad highlights the connectivity of the da Vinci 5 - 21 hour(s) ago
“It’s a system that is still not being used to its maximum capability, which is exciting. That means we can continue evolving,” says Jaschar Shakuri-Rad, DO, FACOS.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0First patient dosed with TLX250-CDx for ccRCC in Australia - 22 hour(s) ago
The first patient was treated with TLX250-CDx at the Olivia Newton-John Cancer Wellness Centre at Austin Health in Melbourne, Australia,
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 14
“It is important as a field that we recognize the potential emotional impact of surgical adverse events,” writes Amy N. Luckenbaugh, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1EMA recommends approval of vibegron for OAB - 1 day(s) ago
Following the positive recommendation, the European Commission will now review the application for vibegron for potential approval in the OAB setting in all EU member states, as well as in Iceland, Liechtenstein, and Norway.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Dr. Neil Baum's 10 tips for being on time as a physician - 1 day(s) ago
“There are opportunities for doctors to become more productive, to see more patients, and to avoid the erosion of their incomes,” writes Neil Baum, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1
“We are hopeful that this therapy will help patients with prostate cancer and that this study will be just the first step towards the effective treatment of other bone tumors,” said Daniel Abate-Daga, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 22024 AUA Annual Meeting Previews - 2 day(s) ago
Video interviews of experts in the field reviewing research being presented at the 2024 AUA Annual Meeting.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 518-gene urine test may reduce unnecessary prostate biopsies - 3 day(s) ago
The MPS2 models demonstrated negative predictive values of 95% to 99% for cancers of grade group 2 or higher and of 99% for cancers of grade group 3 or higher.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
Sanochemia Pharmazeutika has secured the exclusive licensing rights to a new MRI contrast agent based on ferumoxtran for use in patients with prostate cancer. #pcsm #urology #urologist Read more: https://t.co/ZgzMvGluGq